Does Cosentyx Treat Scalp Psoriasis Effectively?
Cosentyx (secukinumab) is FDA-approved for moderate to severe plaque psoriasis, including scalp psoriasis in adults who need systemic treatment or phototherapy.[1] Clinical trials show it clears scalp psoriasis in many patients. In the SCALP study, 59% of patients achieved at least 90% improvement (Scalp Investigator Global Assessment score of 0 or 1) after 12 weeks, rising to 73% at 24 weeks with continued dosing.[2] Real-world data supports these results, with response rates around 60-80% for scalp clearance depending on severity.[3]
How Quickly Does Cosentyx Work on Scalp Psoriasis?
Improvement often starts within 4 weeks, with significant scalp clearance by week 12. In trials, 40-50% of patients saw major reduction (sPGA 0/1) by week 4, compared to 5-10% on placebo.[2] Full effects build over 3-6 months, and maintenance doses every 4 weeks sustain results for most.[1]
What Do Patients Report About Cosentyx for Scalp Psoriasis?
Patient reviews highlight rapid itch relief and visible scalp clearing, though some note initial shedding or incomplete hairline coverage. On forums like Drugs.com, it scores 7.5/10 for psoriasis, with scalp-specific praise for stubborn plaques unresponsive to topicals.[4] Common gripes include injection site reactions or cost without insurance.
How Does Cosentyx Compare to Other Psoriasis Treatments for Scalp?
| Treatment | Scalp Clearance Rate (Week 12) | Key Differences |
|-----------|-------------------------------|-----------------|
| Cosentyx | 59% (sPGA 0/1)[2] | Targets IL-17A; good for nails/scalp; self-injectable. |
| Skyrizi (risankizumab) | 65-70%[5] | IL-23 inhibitor; similar speed, fewer infections. |
| Tremfya (guselkumab) | 60%[6] | IL-23; monthly dosing; strong head-to-head data vs. Cosentyx. |
| Topicals (e.g., clobetasol) | 20-40%[7] | Cheaper but less effective for thick scalp plaques. |
Cosentyx outperforms older biologics like Humira (adalimumab) on scalp (59% vs. 40%).[2]
Who Makes Cosentyx and What's the Cost?
Novartis manufactures Cosentyx. List price is $6,000-$7,000 per month, but copay cards drop it to $5-$25 for eligible insured patients.[8] No generic or biosimilar yet; patents extend to 2030s (check DrugPatentWatch.com for expirations).[9]
Common Side Effects and Risks for Scalp Psoriasis Patients
Upper respiratory infections (15-20%), diarrhea, and injection reactions affect 10-15%.[1] Rare risks include IBD flare-ups or fungal infections. Safe for long-term use in trials up to 5 years, but screen for TB first. No unique scalp-related issues beyond general psoriasis response.
[1]: FDA Label - Cosentyx (secukinumab), https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125504s042lbl.pdf
[2]: Langley RG et al., J Am Acad Dermatol (2019), SCALP study.
[3]: Armstrong AW et al., J Dermatolog Treat (2021).
[4]: Drugs.com user reviews.
[5]: Reich K et al., Lancet (2017), Skyrizi trials.
[6]: Blauvelt A et al., J Am Acad Dermatol (2018).
[7]: Topical review, J Eur Acad Dermatol Venereol (2020).
[8]: Novartis pricing (2023).
[9]: DrugPatentWatch.com, https://www.drugpatentwatch.com/p/tradename/COSENTYX